[go: up one dir, main page]

WO2001051659A3 - Biallelic markers derived from genomic regions carrying genes involved in central nervous system disorders - Google Patents

Biallelic markers derived from genomic regions carrying genes involved in central nervous system disorders Download PDF

Info

Publication number
WO2001051659A3
WO2001051659A3 PCT/IB2001/000116 IB0100116W WO0151659A3 WO 2001051659 A3 WO2001051659 A3 WO 2001051659A3 IB 0100116 W IB0100116 W IB 0100116W WO 0151659 A3 WO0151659 A3 WO 0151659A3
Authority
WO
WIPO (PCT)
Prior art keywords
biallelic markers
genes involved
genomic regions
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2001/000116
Other languages
French (fr)
Other versions
WO2001051659A2 (en
Inventor
Tom Chu
Marta Blumenfeld
Daniel Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Biodevelopment SAS
Original Assignee
Genset SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset SA filed Critical Genset SA
Priority to EP01901330A priority Critical patent/EP1285088A2/en
Priority to CA002395240A priority patent/CA2395240A1/en
Priority to AU26999/01A priority patent/AU2699901A/en
Publication of WO2001051659A2 publication Critical patent/WO2001051659A2/en
Anticipated expiration legal-status Critical
Publication of WO2001051659A3 publication Critical patent/WO2001051659A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides polynucleotides including biallelic markers derived from genes involved in CNS disorders and from genomic regions flanking those genes. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype.
PCT/IB2001/000116 2000-01-13 2001-01-11 Biallelic markers derived from genomic regions carrying genes involved in central nervous system disorders Ceased WO2001051659A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01901330A EP1285088A2 (en) 2000-01-13 2001-01-11 Biallelic markers derived from genomic regions carrying genes involved in central nervous system disorders
CA002395240A CA2395240A1 (en) 2000-01-13 2001-01-11 Biallelic markers derived from genomic regions carrying genes involved in central nervous system disorders
AU26999/01A AU2699901A (en) 2000-01-13 2001-01-11 Biallelic markers derived from genomic regions carrying genes involved in central nervous system disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17585400P 2000-01-13 2000-01-13
US60/175,854 2000-01-13

Publications (2)

Publication Number Publication Date
WO2001051659A2 WO2001051659A2 (en) 2001-07-19
WO2001051659A3 true WO2001051659A3 (en) 2002-12-05

Family

ID=22641928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/000116 Ceased WO2001051659A2 (en) 2000-01-13 2001-01-11 Biallelic markers derived from genomic regions carrying genes involved in central nervous system disorders

Country Status (4)

Country Link
EP (1) EP1285088A2 (en)
AU (1) AU2699901A (en)
CA (1) CA2395240A1 (en)
WO (1) WO2001051659A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553831B2 (en) 2000-06-30 2009-06-30 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2401749A1 (en) 2000-03-23 2001-09-27 Elan Pharmaceuticals, Inc. Compounds and methods to treat alzheimer's disease
NZ523005A (en) 2000-06-30 2004-11-26 Elan Pharm Inc Compounds to treat alzheimer's disease
PE20020276A1 (en) 2000-06-30 2002-04-06 Elan Pharm Inc SUBSTITUTE AMINE COMPOUNDS AS ß-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER
JP2005500319A (en) 2001-06-27 2005-01-06 イーラン　ファーマスーティカルズ、インコーポレイテッド Β-hydroxyamine derivatives useful for the treatment of Alzheimer's disease
EP1492885A2 (en) * 2002-04-05 2005-01-05 University Court of the University of Edinburgh Schizophrenia associated genes
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
CA2957200C (en) 2002-10-16 2020-05-26 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
US20090291432A1 (en) * 2004-06-01 2009-11-26 Queensland University Of Technology Genetic profiles associated with the 957C>T polymorphism in the DRD2 gene
EP2287340A3 (en) * 2005-05-11 2011-03-30 Aarhus Universitet Method for diagnosis and treatment of a mental disease
KR100818275B1 (en) * 2006-09-26 2008-03-31 삼성전자주식회사 A primer set for amplifying a target sequence of norovirus, a probe set specifically hybridizing to the target sequence of norovirus, a microarray in which the probe set is immobilized, and a method for detecting the presence of the norovirus using the probe set
WO2008086579A1 (en) * 2007-01-19 2008-07-24 Queensland University Of Technology Diagnostic methods and agents
ES2702619T3 (en) * 2013-04-22 2019-03-04 Innobioscience Llc Treatment of Alzheimer's disease and cognitive impairment with andrographolides
AU2016294347B2 (en) 2015-07-10 2022-07-28 Ionis Pharmaceuticals, Inc. Modulators of diacyglycerol acyltransferase 2 (DGAT2)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054500A2 (en) * 1998-04-21 1999-10-28 Genset Biallelic markers for use in constructing a high density disequilibrium map of the human genome

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054500A2 (en) * 1998-04-21 1999-10-28 Genset Biallelic markers for use in constructing a high density disequilibrium map of the human genome

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEN Y S ET AL.: "A single nucleotide polymorphism map of a bipolar disorder candidate region on chromosome 18q21.3-22.1", THE AMERICAN JOURNAL OF HUMAN GENETICS, vol. 65, no. 4, October 1999 (1999-10-01), pages A245, XP008001465 *
DATABASE EMBL european molecular biology laboratory; 15 March 1999 (1999-03-15), ZHAO S ET AL.: "Use of BAC end sequences from library RPCI-11 for sequence-ready map building", XP002193666 *
HONG C-J ET AL.: "Association analysis of the 5-HT6 receptor polymorphism (C267T) in mood disorders", AMERICAN JOURNAL OF MEDICAL GENETICS (NEUROPSYCHIATRIC GENETICS), vol. 88, 15 December 1999 (1999-12-15), pages 601 - 602, XP008001533 *
KRUGLYAK L: "THE USE OF A GENETIC MAP OF BIALLELIC MARKERS IN LINKAGE STUDIES", NATURE GENETICS, NEW YORK, NY, US, vol. 17, 1997, pages 21 - 24, XP000920766, ISSN: 1061-4036 *
SHINKAI T ET AL.: "Association study of the 5-HT6 receptor gene in Schizophrenia", AMERICAN JOURNAL OF MEDICAL GENETICS (NEUROPSYCHIATRIC GENETICS), vol. 88, 16 April 1999 (1999-04-16), pages 120 - 122, XP008001467 *
SYVÄNEN A-CH ET AL: "IDENTIFICATION OF INDIVIDUALS BY ANALYSIS OF BIALLELIC DNA MARKERS,USING PCR AND SOLID-PHASE MINISEQUENCING", AMERICAN JOURNAL OF HUMAN GENETICS, UNIVERSITY OF CHICAGO PRESS, CHICAGO,, US, vol. 52, no. 1, 1993, pages 46 - 59, XP002050638, ISSN: 0002-9297 *
TSAI S-J ET AL.: "Association analysis of the 5-HT6 receptor polymorphism C267T in Alzheimer's disease", NEUROSCIENCE LETTERS, vol. 276, 1999, pages 138 - 139, XP001066217 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553831B2 (en) 2000-06-30 2009-06-30 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease

Also Published As

Publication number Publication date
AU2699901A (en) 2001-07-24
WO2001051659A2 (en) 2001-07-19
EP1285088A2 (en) 2003-02-26
CA2395240A1 (en) 2001-07-19

Similar Documents

Publication Publication Date Title
WO2000047771A3 (en) Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
WO2001051659A3 (en) Biallelic markers derived from genomic regions carrying genes involved in central nervous system disorders
WO1999032644A3 (en) Prostate cancer gene
WO2004033649A3 (en) High throughput multiplex dna sequence amplifications
WO2000047772A3 (en) Polymorphic markers of the lsr gene
WO2001066800A3 (en) Human single nucleotide polymorphisms
WO1999054500A3 (en) Biallelic markers for use in constructing a high density disequilibrium map of the human genome
WO2005024068A3 (en) Allele-specific sequence variation analysis
WO2000058508A3 (en) Biallelic markers related to genes involved in drug metabolism
CA2348828A1 (en) Genomic and complete cdna sequences of apm1 and biallelic markers thereof
WO2000058519A3 (en) Charaterization of single nucleotide polymorphisms in coding regions of human genes
WO2002006525A3 (en) Obesity associated biallelic marker maps
WO2004081191A3 (en) Molecular haplotyping of genomic dna
WO2003002721A3 (en) Compositions and methods for inferring a response to a statin
WO2001042511A3 (en) Ibd-related polymorphisms
WO2003042226A3 (en) Single nucleotide polymorphisms in gh-1
WO2001038576A3 (en) Human single nucleotide polymorphisms
WO2003023063A1 (en) Method of judging onset risk of diabetes
WO2002010454A3 (en) Haplotypes of the alas2 gene
WO2002026764A3 (en) Haplotypes of the ccr6 gene
WO2002032928A3 (en) Haplotypes of the hrh1 gene
WO2002053734A3 (en) Methods and compositions for inhibiting neoplastic cell growth
WO2002026766A3 (en) Haplotypes of the sstr4 gene
WO2001079231A3 (en) Haplotypes of the npr1 gene
Szantai et al. Haplotyping of the deoxycytidine kinase gene by multicapillary electrophoresis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 26999/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001901330

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2395240

Country of ref document: CA

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001901330

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP